Copyright
©The Author(s) 2024.
World J Crit Care Med. Dec 9, 2024; 13(4): 97631
Published online Dec 9, 2024. doi: 10.5492/wjccm.v13.i4.97631
Published online Dec 9, 2024. doi: 10.5492/wjccm.v13.i4.97631
Ref. | Number of subjects, age, M/F ratio | Study design/HP strategy | Effects on inflammatory markers | Effects on respiratory markers | Main clinical outcomes |
Barriga-Moreno et al[19] | n = 116, Controls = 84; HP = 32; 57 year (range: 47-71 year); Males: 65% | Matched control retrospective Jafron© HA330 cartridge | Serum creatinine (1.4 mg/dL vs 0.5 mg/dL); Serum ferritin (2868 vs 1675) | NR | Mortality rate: 61% in controls (receiving standard care) vs 31% in HP group |
Chiewroongroj et al[21] | n = 272 | Matched control retrospective | HP patients had less DIC (13% vs 33%; P = 0.046) and less sepsis (38% vs 64%; P = 0.02) | HP patients had reduced mechanical ventilation duration (15 days vs 35 days; P < 0.001) and less pulmonary complications (20% vs 42%; P = 0.04) | Mortality rates did not differ between the groups (33% vs 38%, P = 0.83) |
Controls = 227; HP = 45; 57 year (range: 47-71 year); Males: 65% | Jafron© HA330 cartridge | HP group had a significantly shorter ICU stay (22 days vs 32 days; P = 0.017) | |||
Hayanga et al[20] | n = 100 (63% male); 44 ± 11 year | Multicenter combination of VV-ECMO and CytoSorb hemoadsorption. Two post hoc groups: Early HP: ≤ 87 hours and late HP > 87 hours | Early HP had shorter median duration of mechanical ventilation (7 days)[2-26] than late HP (17 days)[7-37], P = 0.02 | Survival rates were 86% at 30 days and 74% at 90 days. Earlier HP was associated with shorter need for organ support and ICU stay | |
Uysal et al[30] | 55 (34, 61.8%) Mean age 585 ± 12.5 year. Mean (SD), year = 59.6. Male sex, n (%) = 82 (64.1) | Case series. Resin-directed Jafron© (HA330) hemadsorption cartridges | Fibrinogen, LDH, CRP, and platelets decreased after HP | NR | In total, 9 patients (16.4%) survived. Ferritin levels correlated with survival status |
Alavi Darazam et al[22] | 128 (55 HP vs 73 controls). Mean age, (SD), year = 59.6. Male sex, n (%) = 82 (64.1) | Matched control retrospective study. Jafron© (HA330) and CytoSorb® 300 cartridges | NR | Median SpO2 statistically higher in HP group than in the controls and median PaCO2 was lower | Mortality rate in the HP group significantly lower than controls (67.3% vs 89%; P = 0.002). The median length of ICU stay was 8 days in HP group vs 12 days in controls (P < 0.001) |
Mikaeili et al[10] | 68 (35 HP vs 33 controls) | Prospective study | NR | Dyspnea decreased significantly in HP group | Significant mortality rate reduction in HP group compared with controls (37.1% vs 63.6%; P = 0.02) |
Mean age: Control 5748 ± 15.63, 18/15; HP group 56.62 ± 15.60, 23/12; sex (M/F): HP group: 32/12; Control: 18/15 | HA330 D HP for 4 hours, in 3 consecutive days. Early started | Saturation of oxygen (SpO2) and P/F ratio significantly increased after HP unlike the control group | After 2 weeks, imagen lung opacities improved in 55% of the patients in HP vs 15.6% in the controls | ||
Surasit et al[11] | 29 (15 HP vs 14 controls). HP group: 12/15, 54.5 ± 14.4; Control group: 7/7, 64.3 ± 10.2 | Prospective study. HA-330 3 HP sessions. Early started | Except for Hb levels (higher in HP group), blood and inflammatory parameters (CRP, ferritin, LDH, CBC) were not statistically different | NR | Significantly lower 28-day mortality rate in HP group compared to control group. Improvement of CXR RALE score and decreased SOFA score in HP group compared to control group |
Darban et al[29] | 40 patients, 57.5 ± 15.9; year 24/16 | Retrospective cross-sectional study to determine the complications of HP patients with COVID-19 hospitalized in ICU | NR | NR | Arrhythmia, bleeding, thrombocytopenia, and coagulation disorders were the most common short-term complications mostly occurring on the second and third days after HP. Mortality occurred in 20 (50%) patients |
Peng et al[23] | 10 patients, median age 677 year (range = 50-85). Sex (male/female): 8/2 | Case series Cytosorb HP. Median: 3 HPs (range = 1-6) | The level of IL-6 significantly decreased after HP. Lactate levels improved after HP | Significant improvement was found in PaO2/FiO2 [118 (81-220) mmHg vs 163 (41-340) mmHg, P = 0.04] | Albumin mildly decreased after HP. No significant changes were found in WBC |
Abbasi et al[12] | 37 patients, 55 ± 14.1; year 12/25 | Retrospective cross-sectional study. Patients divided into three groups: (1) HP without (MV); (2) HP before MV; and (3) HP after MV | CRP and ferritin significantly improved after HP in the three groups | HR, RR, and PaO2/FIO2, significantly improved after HP in all groups | No statistically significant difference between the three groups in terms of length of hospital stay and ICU stay |
Soleimani et al[13] | 48 patients in total. HP cases: 24; Controls: 24 | Retrospective observational study. HP: HA330 and HA280 filters for four hours | CRP levels decrease in HP patients compared to controls | RR and HR decreased after HP. SpO2 Levels significantly increased after HP. in the and a significant (P = 0.009) | HP improved respiratory distress in patients with severe COVID-19 but has no effect on mortality |
Alharthy et al[24] | 50 patients, 50 ± 9; Sex: Male (n, %): 39 (78%) | Case series | Nonsurvivors had higher levels of inflammatory biomarkers (CRP, ferritin, and IL-6), and more unresolved shock, ARDS | Pulmonary emboli more common in non survivors | Posttherapy values of IL-6 predicted in-hospital mortality for critically ill COVID-19 patients. No side effects of therapy were recorded |
All received CRRT and CytoSorb. Compared outcomes and biomarkers between survivors (39) and non survivors (11) | |||||
Villa et al[25] | 37 patients, 31/6; 59 ± 9 year | Prospective non randomized. Blood purification with AN69ST (oXiris) hemofilter | Levels of IL-6 lowered in the first 24 hours of HP. IL-6 levels correlated with organ function | NR | Early HP treatment yielded the best outcomes. A slight decrease in observed vs predicted mortality rates observed. No complications reported |
Ugurov et al[26] | 15 patients, 13/2; 60 ± 13 year | Case series; Blood purification using the AN69ST (oXiris) hemofilter | CRP (mg/L) pre 109 (73) Decreasing levels of IL-6, IL-8 and TNF-α | Blood purification was associated with decreasing levels of IL-6, IL-8, TNF-α, and CRP | Median intensive care unit length of stay was 9.3 days. 2 out of 15 patients died |
Dai et al[27] | Treatment group: 40/10, 60 ± 13 year; control group: 35/16, 60 ± 15 year | Case-control multicenter, prospective; Plasma exchange + HP (50 treated + 51 controls) | IL-6 Level decreased in the treatment group and increased in the control group | No statistical differences in the duration of invasive assisted ventilation between the two groups | The 28-day mortality rates were 16% (8/50) in the treatment group and 50.98% (26/51) in the control group |
Hashemian et al[14] | 14 patients, 9/6; 58 ± 12 year | Case-series Plasmapheresis Cytosorb | Inflammatory mediators (CRP, TNF-, IL-6, and Ferritin) were significantly reduced after plasmapheresis within a week | Plasmapheresis was associated with significant and rapid improvements in oxygenation status | Nine out of fifteen patients on NIPPV survived while the six patients undergoing IMV died |
De Rosa et al[15] | 12 patients with COVID-19 + septic shock 9/3; 60 ± 10 year | Case series Polymyxin-B HP (PMX-HP) | SOFA score progressively improved over the next 120 hours following PMX-HP and it was | NR | COVID-19 patients with endotoxic shock, PMX-HP was associated with organ function recovery, hemodynamic improvement, and contemporary EAA level reduction. No PMX-HP-related complications were observed |
Asgharpour et al[28] | 11 patients, 57 ± 18 year | Cases series; Tree sessions of extracorporeal resin-directed hemoadsorption | Serum IL-6 and CRP improved after intervention | Mean SpO2 increased after the three HP sessions | Six out of ten patients improved after the intervention |
Katagiri et al[16] | 15 patients, 66 (47) year | Case series Toramixyn | Except for one non-survivor, IL-8, IL-10, and IL-17 Levels remained almost unchanged or trended downward | NR | 25% (NR) |
Guo et al[17] | 17 patients, 62 ± 14 year | Case series | 32 cytokines (including IL-6 and TNF-α) out of 34 dosed were significantly decreased after each ALS course | NR | 100% |
- Citation: Vásquez-Torres J, Dávila-Collado R, Abdalah-Perez L, Jarquin-Duran O, Latino JS, Espinoza JL. Beyond conventional care: The therapeutic potential of hemoperfusion in severe COVID-19. World J Crit Care Med 2024; 13(4): 97631
- URL: https://www.wjgnet.com/2220-3141/full/v13/i4/97631.htm
- DOI: https://dx.doi.org/10.5492/wjccm.v13.i4.97631